This podcast episode dives into the topic of subcutaneous immunoglobulins (SCIG). More precisely, we discuss the application of HyQvia®, an innovative medication for the subcutaneous administration of immunoglobulins facilitated by hyaluronidase. In contrast to intravenous administration, HyQvia® allows for administration of larger volumes and longer treatment intervals due to its formulation containing hyaluronidase. The episode gives a thorough introduction to this treatment method and provides insights into the initial experiences of our guest expert Dr. med. Thomas Hauser.
Moderator: Dr. med. Marcus Kühn, Specialist in Allergology and Clinical Immunology at Löwenpraxis, Lucerne (website).
Guest: Dr. med. Thomas Hauser, Specialist in Allergology, Immunology and Internal Medicine at Immunologie-Zentrum Zürich (website).
Brightcove Video
Resources and Links:
[1] Krivan G, Jolles S, Granados EL, Paolantonacci P, Ouaja R, Cissé OA, Bernatowska E. New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. Am J Clin Exp Immunol. 2017 Nov 1;6(5):76-83. PMID: 29181272; PMCID: PMC5698561.
[2] Devonshire AL, Makhija M. Approach to primary immunodeficiency. Allergy Asthma Proc. 2019 Nov 1;40(6):465-469. Doi: 10.2500/aap.2019.40.4273. PMID: 31690396.
[3] Epland K, Suez D, Paris K. A clinician's guide for administration of high-concentration and facilitated subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency diseases. Allergy Asthma Clin Immunol. 2022 Sep 30;18(1):87. doi: 10.1186/s13223-022-00726-7. PMID: 36180928; PMCID: PMC9526304.
HyQvia® prescribing information: www.swissmedicinfo.ch
Healthcare professionals may request a complete copy of the cited literature from the pharmaceutical company.
C-APROM/CH/HYQ/0015_06/2024